Skip to main content
SYRE
NASDAQ Life Sciences

Director-Affiliated Fund Liquidates $399.7M in Spyre Therapeutics Common Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$86.5
Mkt Cap
$8.428B
52W Low
$14
52W High
$102.06
52W Position info
518% above low
Off High info
15% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

SYRE has more than doubled off its 52-week low of $14 on elevated volume (2.1× avg).

Summary

A director-affiliated fund, Fairmount Healthcare Fund II L.P., sold nearly $400 million worth of Spyre Therapeutics common stock, liquidating its direct common stock holdings.


Key Events · Ownership and Investor Activity · SYRE

  • Director-Affiliated Fund Liquidates Common Stock Holdings

    Fairmount Healthcare Fund II L.P., associated with company directors, sold 4,684,781 shares of common stock for $399,658,667.11 at an average price of $85.31 per share, bringing its direct common stock ownership to zero. This represents 5.426% of the company's market capitalization.

  • Conversion of Preferred Stock Preceded Sale

    Prior to the open market sale, Fairmount Healthcare Fund II L.P. converted 16,667 shares of Series B Preferred Stock into 666,680 shares of common stock for no cash consideration.

  • Follows Recent Positive News and Offering

    This large sale occurs after Spyre Therapeutics reported highly positive Phase 2 clinical data for SPY001 and SPY002 in April and June, respectively, and completed a $435.3 million public offering in May.


Analysis · SYRE · Life Sciences

Fairmount Healthcare Fund II L.P., a fund associated with company directors, executed a substantial sale of Spyre Therapeutics common stock, liquidating its direct common stock holdings. This significant disposition, following a conversion of preferred shares, represents a material reduction in their stake and could be interpreted as a move to realize gains after recent positive clinical data and a successful public offering. While the fund still holds convertible preferred stock, the complete exit from common stock is a notable event.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 46.9% of the 1569 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SYRE was trading at $86.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4B. The 52-week trading range was $14.00 to $102.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SYRE - Latest Insights

SYRE
Nov 03, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $103.00 info
Change: +$3.27 (+3%) info
Market Cap: $9.863B info
SYRE
Nov 03, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $103.00 info
Change: +$3.27 (+3%) info
Market Cap: $9.863B info
SYRE
Oct 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $80.51
Real-time Price: $103.00 info
Change: +$22.49 (+28%) info
Market Cap: $9.863B info
SYRE
Oct 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $80.11
Real-time Price: $103.00 info
Change: +$22.89 (+29%) info
Market Cap: $9.863B info
SYRE
Oct 06, 2026, 11:53 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $81.16
Real-time Price: $103.00 info
Change: +$21.84 (+27%) info
Market Cap: $9.863B info